Article
Pharmacogenetic markers of PEG-asparaginase toxicity in Brazilian pediatric ALL: insights from a multicenter prospective cohort study.
Pharmacogenomics - 1 Jan 2025
Cecconello Daiane Keller, de Souza Silva Klerize Anecely, de Senna Evelin Cristine Mendonça, Carlotto Lucas Alfeu, de Souza Amanda Másculo, Lins Mecneide Mendes, Magalhães Isis Maria Quezado Soares, de Sousa Ana Virgínia Lopes, Epelman Sidnei, Cristofani Lilian, Barros Tais Tereziano, Pianovski Mara, Moreira Larissa Polis, Rechenmacher Ciliana, Daudt Liane Esteves, Michalowski Mariana Bohns
Abstract excerpt
AIMS: Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer. Although PEG-asparaginase (PEG-ASNase) is a key drug in treatment, hypersensitivity reactions, pancreatitis, and silent inactivation remain major challenges. Interindividual genetic variability influences drug metabolism and toxicity, and pharmacogenetic research aims to identify these variants early to predict specific responses...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
